LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
9301-251-999	10/591,800

APPLICANT

Dai *et al.*

FILING DATE	ART UNIT
March 7, 2005	~~1634~~

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A03	2003/0224374 A1	12/04/03	Dai et al.	
	A04	2006/040302 A1	02/23/06	Botstein et al.	
	A05	7,171,311 B2	08/07/08	Dai et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B05	WO 2006/084272 A2	8/10/06	Rosetta Inpharmatics LLC		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C45	AGENDIA BV, press release dated February 5, 2007, "Agendia's MamaPrint breast cancer prognosis test cleared by U.S. Food and Drug Administration (FDA) -- MammaPrint® is the first multi-gene expression test to receive market clearance by the FDA" [online]., **2 pages.** Retrieved from the Internet: <http://www.agendia.com/en/Agendia/Press-Releases/Press-Release>	
	C46	ALEXE et al., 2006, "Breast cancer prognosis by combinatorial analysis of gene expression data," Breast Cancer Research, Current Science 8: 1-20	
	C47	BARRETT et al., 2003, "Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression," Drug Discovery Today 8(3): 134-141	
	C48	BERTUCCI et al., 2000, "Gene expression profiling of primary breast cancer carcinomas using arrays of candidate genes," Human Molecular Genetics 9: 2981-2991	
	C49	COOPER, 2001, "Applications of microarray technology in breast cancer research," Breast Cancer Research 3: 158-175	
	C50	GEO EXPRESSION, 2002, "Affymetrix GeneChip Human Genome U133 Array Set HG-U133A" [online]. [Retrieved 2006-03-01]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi>.	
	C51	GRUVBERGER et al., 2002, "Expression profiling to predict outcome in breast cancer: the influence of sample selection," Breast Cancer Research, Current Science 5(1): 23-26.	
	C52	HELDENFALK et al., 2001, "Gene-Expression Profiles in Hereditary Breast Cancer," N. Engl. J. Med. 344: 539-548	
	C53	HUANG et al., 2003, "Gene expression predictors of breast cancer outcomes," The Lancet 361: 1590-96	
	C54	INTERNATIONAL Search Report dated November 23, 2005, issued in International Application No. PCT/US05/07894, **4 pages.**	
	C55	JAHKOLA et al., 1996, "Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis," Intl J. Cancer, 69(6): 445-447	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CS/

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9301-251-999	APPLICATION NO. 10/591,800
	APPLICANT Dai *et al.*	
	FILING DATE March 7, 2005	ART UNIT ~~1631~~

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C56	KEYS et al., 1983, "Clinical Oncology, Chapter 12 Breast Cancer," Edited by: Philip Rubin , 6th edition, American Cancer Society, pp. 120-128, 133, and 506	
	C57	KHAN et al., 2001, "Classification and diagnostics prediction of cancers using gene expression profiling and artificial neural networks," Nature Medicine 7: 673-679	
	C58	OFFICE ACTION dated October 19, 2005, in U.S. application no. 10/342,887, filed on January 15, 2003, now U.S. patent no. 7,171,311 B2, issued on January 30, 2007	
	C59	PEROU et al., 1999, "Distinctive gene expression patterns in human mammary epithelial cells and breast cancers," Proc Natl Acad Sci USA 96: 9212-9217	
	C60	SILVESTRINI et al., 1996, "Validation of P53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers," Clin. Cancer Res. 2: 2007-2013	
	C61	SUPPLEMENTARY Partial European Search Report dated July 2, 2007, issued in European Patent Application No. 02746538.4-2204, the European regional phase of PCT/US02/018947 6 pages.	
	C62	SUPPLEMENTARY European Search Report dated August 21, 2008, issued in European Patent Application No. 04702566.3-2403, the European regional phase of PCT/US2004/001100 , 5 pages.	
	C63	SUPPLEMENTARY European Search Report dated August 22, 2008, issued in European Patent Application No. 05725207.4-2403, the European regional phase of PCT/US2005/007894 , 7 pages.	
	C64	U.S. FOOD and Drug Administration, press release dated February 6, 2007, "FDA Clears Breast Cancer Specific Molecular Prognostic Test" [online]. [Retrieved 11/28/2007], 2 pages. Retrieved from the Internet: <http://www.fda.gov/bbs/topics/NEWS/2007/NEW01555.html>	
	C65	VAN'T VEER et al., 2002, "Expression profiling changes treatment in breast cancer," Anal. Cell. Pathol. 25: 227-228	

NYI-4162491v1

EXAMINER	/Carolyn Smith/	DATE CONSIDERED	02/25/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CS/